← Eichor
Study identifier: NCT07660198 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents

Condition: Pneumococcal Disease  ·  Sponsor: Pfizer

PhasePhase 3
Planned participants1200
Who can joinAll sexes, 15 Months to 17 Years
Healthy volunteersYes

About this study

The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in children when compared to the pneumococcal vaccine that is currently in use, 20vPnC (Prevnar 20®). This study will test if the new pneumococcal vaccine is as safe as the one that is currently in use. It will also assess how the new vaccine works in comparison to the one that is currently in use. To measure how the new pneumococcal vaccine compares to the current one, blood samples will be used to measure the body's ability to create proteins to fight those germs. This new vaccine can possibly provide additional protection against germs that cause pneumococcal disease that are not included in the vaccines that are currently given to children. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae This study is seeking participants who: * Are children aged 15 months to 18 years. * May or may not have received any doses of pneumococcal conjugate vaccine (PCV) in the past. The study will be conducted in the United States, Puerto Rico, and other countries. Participants will be assigned to 1 of 3 groups based on age: Group 1: 15 months to less than 2 years (about 300 participants) Group 2: 2 years to less than 5 years (about 300 participants) Group 3: 5 years to less …

This description comes directly from the study's public registry record.

Talk to the study team

Pfizer CT.gov Call Center  ·  1-800-718-1021  ·  ClinicalTrials.gov_Inquiries@pfizer.com

Always discuss trial participation with your own doctor first.

Locations (44)

Alabama Clinical Therapeutics, LLC Birmingham Pediatric AssociatesBirmingham, Alabama, United StatesRecruiting
Apex Research GroupFair Oaks, California, United StatesRecruiting
Orange County Research InstituteOntario, California, United StatesRecruiting
Riveldi and AssociatesMiami Lakes, Florida, United StatesNot Yet Recruiting
Indago Research & Health Center, IncMiami Lakes, Florida, United StatesRecruiting
Medical Research PartnersAmmon, Idaho, United StatesNot Yet Recruiting
Bingham Memorial HospitalBlackfoot, Idaho, United StatesRecruiting
ASR, LLCBoise, Idaho, United StatesRecruiting
Kentucky Pediatric/ Adult ResearchBardstown, Kentucky, United StatesRecruiting
AvacareCovington, Louisiana, United StatesNot Yet Recruiting
Velocity Clinical Research, LafayetteLafayette, Louisiana, United StatesRecruiting
LSU Health Shreveport Clinical Trials OfficeShreveport, Louisiana, United StatesRecruiting

+ 32 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07660198